Studies on spirolactone steroid antagonists in ACTH-induced hypertension in sheep.
This study investigated the anti-mineralocorticoid potency and haemodynamic effects of a series of mineralocorticoid antagonists of the spirolactone type (RU 28318, spironolactone, K-prorenoate, K-canrenoate and canrenone), for their ability to prevent the development of ACTH-induced hypertension in conscious sheep. In vivo bioassay, using aldosterone dependent changes in parotid salivary [Na+]/[K+] of sodium depleted adrenalectomized sheep, showed spironolactone was the most potent anti-mineralocorticoid tested. Infusions of the antagonists at equal doses alone for 4 days demonstrated that none affected mean arterial pressure, except for K-prorenoate which exhibited slight pressor activity. All the antagonists produced a natriuresis. Some of the steroid antagonists of the spirolactone group blocked the development of ACTH hypertension in sheep, spironolactone being the most effective. This study provides additional evidence for an essential mineralocorticoid component in ACTH-induced hypertension.
Reid
A F
AF
Howard Florey Institute of Experimental Physiology and Medicine, University of Melbourne, Australia.
Coghlan
J P
JP
Spence
C D
CD
Whitworth
J A
JA
Scoggins
B A
BA
D000324:Adrenocorticotropic Hormone; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D004573:Electrolytes / Q000097:blood / Q000652:urine; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006973:Hypertension / Q000139:chemically induced / Q000503:physiopathology*; D008901:Mineralocorticoids / Q000037:antagonists & inhibitors; D012463:Saliva / Q000032:analysis; D012756:Sheep; D013148:Spironolactone / Q000037:antagonists & inhibitors* / Q000494:pharmacology
D004573:Electrolytes; D008901:Mineralocorticoids; D013148:Spironolactone; D000324:Adrenocorticotropic Hormone